On November 8, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, reported the appointment of Dr. Sandra Silberman as Chief Medical Officer ("CMO") in charge of New Products (Press release, Moleculin, NOV 8, 2017, View Source;-new-products [SID1234521745]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Dr. Silberman is a highly experienced, well-esteemed oncologist and CMO," commented Walter Klemp, Chairman and CEO of Moleculin. "Among her many accomplishments, she was the project leader for Gleevec, a blockbuster cancer drug. We’ve benefitted from her guidance during her time on our Science Advisory Board, but as we have gained momentum with our WP1066 and WP1122 Portfolios, we now need the focus of a highly qualified CMO. We are honored to have such an accomplished physician leading these planned clinical projects."
Mr. Klemp concluded, "This appointment allows Dr. Robert Shepard, our CMO in charge of Hematology, to devote his full attention to the clinical trials of Annamycin."
Dr. Silberman’s career in clinical development began at Pfizer, Inc., where she oversaw the initiation of Tarceva clinical trials. She then led the global development of Gleevec at Novartis. Sandra was the first Vice President and Global Therapeutic Area Head in Oncology at Eisai, a role in which she advanced five original compounds into Phases I through III, gaining the first approval for Eisai’s proprietary drug, Halavan. Subsequently, she served as a senior advisor to a number of biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone, Roche, and numerous biotech companies as an independent industry consultant. She joined Quintiles in 2009 as the Vice President of Oncology and Global Head of Translational Medicine in the newly formed Innovation division, overseeing drug development and novel technologies for new partnerships with the pharmaceutical and biotechnology industries. Sandra earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively. Her major focus of investigation and doctoral thesis was in the burgeoning area of tumor immunology. She received her M.D. from Cornell University Medical College, completing a postdoctoral training and her fellowship in hematology/oncology at the Brigham & Women’s and the Dana Farber Cancer Institute in Boston. She continued to do research in tumor immunology with a clinical investigator award from the NIH and became an Instructor in Medicine at Harvard Medical School. She then served as an attending physician at Yale University Hospital. Sandra has continued in clinical practice throughout her career in industry, and is currently an attending physician in the Hematology/Oncology clinic at the Duke VA in Durham, NC.